A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, researchers report.
Click here for original story, CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
Source: ScienceDaily